Christopher Liu
Stock Analyst at LUCID CAPITAL MARKETS
(2.90)
# 1,315
Out of 5,176 analysts
10
Total ratings
80%
Success rate
36.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Initiates: Buy | $14 | $6.66 | +110.21% | 1 | Mar 2, 2026 | |
| EXEL Exelixis | Upgrades: Outperform | $48 | $42.79 | +12.19% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $20.14 | -0.70% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $4.07 | +121.13% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $2.65 | +277.36% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $9.60 | +87.50% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $31.39 | -13.99% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $98.00 | -57.14% | 1 | Aug 8, 2023 |
Relmada Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $14
Current: $6.66
Upside: +110.21%
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $42.79
Upside: +12.19%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $20.14
Upside: -0.70%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $4.07
Upside: +121.13%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $2.65
Upside: +277.36%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $9.60
Upside: +87.50%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $31.39
Upside: -13.99%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $98.00
Upside: -57.14%